The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28169162 |
86 |
Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
Askat |
27020304 |
31 |
Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. |
Eli Lilly |
24900798 |
1 |
Selective EP4 Antagonist May Be Useful in Treating Arthritis and Arthritic Pain. |
Therachem Research Medilab (India) |
22546206 |
162 |
Synthesis and evaluation of¿-lactam analogs of PGE2 as EP4 and EP2/EP4 agonists. |
Minase Research Institute |
22386979 |
104 |
Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists. |
Minase Research Institute |
22204740 |
135 |
Synthesis and evaluation of novel modified¿-lactam prostanoids as EP4 subtype-selective agonists. |
Minase Research Institute |
20218623 |
68 |
Emerging targets in osteoporosis disease modification. |
Amgen |
20163116 |
116 |
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. |
Merck Frosst Centre For Therapeutic Research |
19250823 |
72 |
Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. |
Pfizer |
16442794 |
95 |
Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats. |
Pfizer |
15857112 |
55 |
Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
Fujisawa Pharmaceutical |